	US 11,732,037 B2
	Weight loss regimen
Philipp E. Scherer, Dallas, TX (US); and Shangang Zhao, Dallas, TX (US)
Assigned to Board of Regents, The University of Texas Svstem, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Dec. 16, 2020, as Appl. No. 17/124,483.
Application 17/124,483 is a continuation of application No. PCT/US2019/037223, filed on Jun. 14, 2019.
Claims priority of provisional application 62/685,996, filed on Jun. 16, 2018.
Prior Publication US 2021/0395359 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 3/04 (2006.01); C07K 16/26 (2006.01); A61P 3/10 (2006.01)

CPC C07K 16/26 (2013.01) [A61P 3/04 (2018.01); A61P 3/10 (2018.01)]

4 Claims

1. A method of treating obesity, the method comprising administering to an obese person a therapeutic leptin neutralizing monoclonal antibody, wherein the antibody effects a partial inhibition of circulating leptin in the person.